Vermillion Sets Second Quarter 2014 Conference Call for Thursday, August 14, 2014

AUSTIN, Texas, July 31, 2014 /PRNewswire/ -- Vermillion, Inc. VRML, a multivariate diagnostics company focused on gynecologic cancers and women's health, will hold a conference call on Thursday, August 14, 2014, at 4:30 p.m. Eastern time to discuss results for the second quarter ended June 30, 2014. Financial results will be issued in a press release prior to the call.

Vermillion's Chairman, President and CEO James LaFrance will host the call, followed by a question and answer period.

Date: Thursday, August 14, 2014
Time: 4:30 p.m. Eastern time (3:30 p.m. Central time)
Dial-in number: 1-888-297-0360
International dial-in number: 1-719-325-2306
Conference ID: 7027308
Webcast: http://edge.media-server.com/m/p/7m5vxsyv/lan/en

The conference call will be webcast live and available for replay via the investor section of the company's website at www.vermillion.com.

Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Vermillion, Inc. at 512-519-0400.

A replay of the call will be available approximately two hours after the call until August 28, 2014.

Toll-free replay number: 1-877-870-5176
International replay number: 1-858-384-5517
Replay ID: 7027308

About Vermillion

Vermillion, Inc. VRML is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in gynecologic oncology and women's health.

The company's lead diagnostic, OVA1^®, is a blood test for pre-surgical assessment of ovarian tumors for malignancy, using an innovative algorithmic approach. As the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, OVA1 represents a new class of software-based diagnostics. For additional information, including published clinical trials, visit www.vermillion.com.  

Investor Relations Contact:
Eric Schoen
Tel 1-512-519-0424
eschoen@vermillion.com

SOURCE Vermillion, Inc.